News stories about Savara (NASDAQ:SVRA) have been trending somewhat negative on Wednesday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Savara earned a media sentiment score of -0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.4969102007707 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
Savara (SVRA) traded up $0.91 on Wednesday, hitting $13.41. 192,951 shares of the stock were exchanged, compared to its average volume of 172,125. The stock has a market cap of $361.43, a price-to-earnings ratio of -3.20 and a beta of -0.26. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15. Savara has a 12-month low of $4.60 and a 12-month high of $17.19.
A number of research firms recently weighed in on SVRA. BidaskClub lowered shares of Savara from a “buy” rating to a “hold” rating in a research note on Friday, January 19th. Ladenburg Thalmann Financial Services began coverage on shares of Savara in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective for the company. ValuEngine upgraded shares of Savara from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Finally, Canaccord Genuity lifted their price objective on shares of Savara from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $23.58.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/mast-therapeutics-svra-earns-media-impact-score-of-0-06-4.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.